Polymer-Linked cGMP Multimers for Selective PKG Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cGMP analogues lack the ability to effectively modulate multiple targets of the cGMP signaling cascade, particularly PKG Iβ and II, and often suffer from off-target effects and poor synthetic accessibility, limiting their use in research and therapeutic applications.
Innovation Solution
Development of polymer linked multimeric guanosine-3′,5′-cyclic monophosphate (PLM) analogues, including di-, tri-, and tetramers, with tailored spacer lengths and functional groups to enhance activation potential for PKG Iα, Iβ, and II, while allowing for functionalization with reporting groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Power
If cGMP analogues are designed to target specific PKG isoforms, then activation potential for main target is improved, but off-target effects increase and selectivity decreases
Solution Approach 1:
The invention segments the cGMP signaling cascade into multiple discrete targets (PKG Iα, Iβ, and II isoforms) and designs specific cGMP analogues for each isoform. By creating isoform-specific compounds rather than broad-spectrum activators, the patent reduces off-target effects while maintaining high activation potential for the intended target.
Solution Approach 2:
The patent applies local quality by introducing specific molecular modifications at particular positions on the cGMP molecule (such as substitutions at the 8-position, 2'-position, or 5'-position) to achieve isoform-selective binding. These localized structural changes confer specificity to individual PKG isoforms while preserving the core cGMP pharmacophore for activation.
2Manufacturing precision
If a large set of cGMP analogues is tested to achieve maximum effect, then target specificity and activation potential are improved, but research time and complexity increase
Solution Approach 1:
The patent performs preliminary action by pre-designing and synthesizing a focused library of cGMP analogues with specific structural features predicted to confer isoform selectivity. Rather than testing random analogues, the invention employs structure-activity relationship (SAR) insights to pre-optimze compounds for specific PKG isoforms, thereby reducing the number of compounds that need to be screened while achieving high target specificity.
3Power
If compounds with improved activation potential are used, then less substance is needed, but off-target effects and extra cellular bindings increase
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters of cGMP analogues (such as substituent types at different positions, spacer lengths in multimeric structures, and charge distribution) to optimize the balance between activation potential and selectivity. By tuning these parameters, the invention achieves high potency with minimal off-target effects.
4Power
If polymer linked multimers are designed to address multiple binding sites, then activation potential for multiple targets is improved, but molecular complexity and synthetic difficulty increase
Solution Approach 1:
The patent employs the nested doll principle by constructing multimeric cGMP analogues where multiple cGMP units are linked through spacer moieties in a hierarchical manner. The core cGMP pharmacophore is nested within a larger multimeric structure, allowing each unit to potentially bind to separate PKG isoforms while maintaining a modular design that facilitates synthesis and characterization.
Data Source
AI summary
Embodiments of the invention are directed to new polymer linked multimeric guanosine-3′,5′-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being activators of cGMP dependent protein kinase (PKG), and related monomeric precursors thereof. The invention is also directed to related monomeric compounds, which may also show modulating activity and/or may serve as monomeric precursors of the multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces.